Background SB5 is a biologic agent developed as a biosimilar of the adalimumab reference product (ADL). The 24-week results of Phase III study results have been reported 1. Objectives To evaluate the ...

Background SB5 is a biologic agent developed as a biosimilar of the adalimumab reference product (ADL). Pharmacokinetic equivalence was demonstrated in a phase I study in healthy subjects 1. Primary ...

The adalimumab biosimilar SB5 was reported to be as safe and effective as the reference product in a review of randomized controlled trials and real-world studies on immune-mediated inflammatory ...

A phase 3 trial of SB5, a proposed biosimilar to adalimumab (AbbVie’s Humira), showed that SB5 was equivalent to its reference with respect to the American College of Rheumatology's 20% improvement ...

Based on the disclosed top-line findings, SB5 met primary objectives and secondary benchmarks, indicating comparable pharmacokinetic profiles for patients switching between SB5 and AbbVie’s Humira.